Literature DB >> 7731724

Consistent loss of the wild type allele in breast cancers from a family linked to the BRCA2 gene on chromosome 13q12-13.

N Collins1, R McManus, R Wooster, J Mangion, S Seal, S R Lakhani, W Ormiston, P A Daly, D Ford, D F Easton.   

Abstract

A small proportion of breast cancer is attributable to the inheritance of dominant, high penetrance susceptibility genes. One of these genes, BRCA2, has recently been localised by genetic linkage analysis to chromosome 13q12-13. This is a region known to exhibit loss of heterozygosity in 20-40% sporadic breast cancers. In this study, we have examined cancers from a family showing strong evidence of linkage to BRCA2. LOH was seen in seven out of eight informative cancers. In all cases the allele lost was the wild type allele that does not segregate with the disease in the family. The data suggest that both alleles of BRCA2 are inactivated in cancers, the pattern expected of a recessive oncogene or tumour suppressor gene.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7731724

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  79 in total

1.  Gross chromosomal rearrangements and genetic exchange between nonhomologous chromosomes following BRCA2 inactivation.

Authors:  V P Yu; M Koehler; C Steinlein; M Schmid; L A Hanakahi; A J van Gool; S C West; A R Venkitaraman
Journal:  Genes Dev       Date:  2000-06-01       Impact factor: 11.361

Review 2.  Homologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteins.

Authors:  Rohit Prakash; Yu Zhang; Weiran Feng; Maria Jasin
Journal:  Cold Spring Harb Perspect Biol       Date:  2015-04-01       Impact factor: 10.005

Review 3.  Analysis of genetic linkage and somatic loss of heterozygosity in affected pairs of first-degree relatives.

Authors:  K Rohde; M D Teare; M Santibáñez Koref
Journal:  Am J Hum Genet       Date:  1997-08       Impact factor: 11.025

4.  Modifying effect of reproductive risk factors on the age at onset of breast cancer for German BRCA1 mutation carriers.

Authors:  J Chang-Claude; H Becher; N Eby; G Bastert; J Wahrendorf; U Hamann
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

5.  Methylation status of CpG islands at sites -59 to +96 in exon 1 of the BRCA2 gene varies in mammary tissue among women with sporadic breast cancer.

Authors:  Nurhan Cucer; Serpil Taheri; Engin Ok; Yusuf Ozkul
Journal:  J Genet       Date:  2008-08       Impact factor: 1.166

6.  Brca2 is coordinately regulated with Brca1 during proliferation and differentiation in mammary epithelial cells.

Authors:  J V Rajan; M Wang; S T Marquis; L A Chodosh
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-12       Impact factor: 11.205

7.  A high-throughput pharmaceutical screen identifies compounds with specific toxicity against BRCA2-deficient tumors.

Authors:  Bastiaan Evers; Eva Schut; Eline van der Burg; Tanya M Braumuller; David A Egan; Henne Holstege; Pauline Edser; David J Adams; Richard Wade-Martins; Peter Bouwman; Jos Jonkers
Journal:  Clin Cancer Res       Date:  2009-12-15       Impact factor: 12.531

8.  Tumor characteristics as an analytic tool for classifying genetic variants of uncertain clinical significance.

Authors:  Robert M W Hofstra; Amanda B Spurdle; Diana Eccles; William D Foulkes; Niels de Wind; Nicoline Hoogerbrugge; Frans B L Hogervorst
Journal:  Hum Mutat       Date:  2008-11       Impact factor: 4.878

9.  Frequent occurrence of BRCA2 linkage in Icelandic breast cancer families and segregation of a common BRCA2 haplotype.

Authors:  J Gudmundsson; G Johannesdottir; A Arason; J T Bergthorsson; S Ingvarsson; V Egilsson; R B Barkardottir
Journal:  Am J Hum Genet       Date:  1996-04       Impact factor: 11.025

10.  Clinically applicable models to characterize BRCA1 and BRCA2 variants of uncertain significance.

Authors:  Andrew D Spearman; Kevin Sweet; Xiao-Ping Zhou; Jane McLennan; Fergus J Couch; Amanda Ewart Toland
Journal:  J Clin Oncol       Date:  2008-09-29       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.